Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin
M A Kelley1, D J Weber, P Gilligan
1Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC 27599-7030, USA. Meera_Kelley@med.unc.edu
Abstract:
Streptococcus pneumoniae strains have exhibited decreasing susceptibility to penicillins and macrolides during the past several years. We reviewed the medical charts of all patients with pneumococcal bacteremia who were admitted to a university hospital over a period of 1 year, to identify failures of outpatient therapy. Of 41 patients admitted with pneumococcal bacteremia, 4 had previously taken either azithromycin or clarithromycin for 3-5 days. All 4 had pneumococcal strains that exhibited low-level resistance to macrolide antibiotics. Among pneumococci, low-level resistance to macrolides can lead to clinical failure, and resistance to macrolides should be considered during the selection of empiric therapy for patients with presumed pneumococcal infections.
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Acute Pyelonephritis II: Diagnostic Studies and Management
Atypical Pneumonia
Mechanism of Antibiotic Resistance in MRSA
Cryptococcal Meningitis
Clinical Significance of Antibiotic Resistance


